AVPR2 and autosomal dominant polycystic kidney disease: For example, Tolvaptan, a vasopressin V2 receptor antagonist, reduces cAMP levels and is currently used to slow the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD) [102].